In addition, the EAM group in “early” stages (3W) developed severe cardiac dysfunction (Figure 2), including decrease of EF and FS, ventricular dilation, and hypertrophy with reduced RIP1, RIP3, and MLKL expression. This evidence concerns the gene RIPK1 and cardiac hypertrophy.